Periprosthetic Joint Infection, or PJI, is considered to be one of the biggest challenges facing orthopaedics today. In spite of technological advances in implants and techniques, the incidence of PJI is increasing. Moreover, due to the incidence of culture negative infections, challenges of screening tests when patients have inflammatory conditions, or premature administration of antibiotics, the diagnosis of PJI remains a major obstacle in clinical practice.
Zimmer Biomet is committed to assisting surgeons and infection specialists in diagnosing PJI. With the Synovasure Alpha Defensin Test, the company offers the first and only test specifically designed and validated for the diagnosis of PJI. The Synovasure Alpha Defensin Test offers sensitivity and specificity in the high 90%’s, based on the MSIS criteria for infection.
Zimmer Biomet’s Synovasure Alpha Defensin test was developed as a new diagnostic technology, based on proteins, or biomarkers, that are released by activated neutrophils at the site of infection. Offering high accuracy1, performance far exceeding current tests, and 24 hour turn around for results, the addition of Synovasure Alpha Defensin Test to their diagnostic assessment, gives health care providers more confidence in the proper diagnosis of PJI, leading to appropriate treatment of this challenging complication.